Scientists report that antibodies that displayed high levels of cross-reactivity with the SARS-CoV-2 spike, were incapable of neutralizing pseudoviruses expressing SARS-CoV-2 spike proteins and were unlikely to mediate ADE via FcγRII receptor engagement.
[Scientific Reports]
6445218
{6445218:EQS4SDXT}
apa
50
1
163372
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-f04439b3ca8755ffaadbfb433eb9f790%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22EQS4SDXT%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mannar%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMannar%2C%20D.%2C%20Leopold%2C%20K.%2C%20%26amp%3B%20Subramaniam%2C%20S.%20%282021%29.%20Glycan%20reactive%20anti-HIV-1%20antibodies%20bind%20the%20SARS-CoV-2%20spike%20protein%20but%20do%20not%20block%20viral%20entry.%20%3Ci%3EScientific%20Reports%3C%5C%2Fi%3E%2C%20%3Ci%3E11%3C%5C%2Fi%3E%281%29%2C%2012448.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-91746-7%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-91746-7%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DEQS4SDXT%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Glycan%20reactive%20anti-HIV-1%20antibodies%20bind%20the%20SARS-CoV-2%20spike%20protein%20but%20do%20not%20block%20viral%20entry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiraj%22%2C%22lastName%22%3A%22Mannar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karoline%22%2C%22lastName%22%3A%22Leopold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sriram%22%2C%22lastName%22%3A%22Subramaniam%22%7D%5D%2C%22abstractNote%22%3A%22The%20SARS-CoV-2%20spike%20glycoprotein%20is%20a%20focal%20point%20for%20vaccine%20immunogen%20and%20therapeutic%20antibody%20design%2C%20and%20also%20serves%20as%20a%20critical%20antigen%20in%20the%20evaluation%20of%20immune%20responses%20to%20COVID-19.%20A%20common%20feature%20amongst%20enveloped%20viruses%20such%20as%20SARS-CoV-2%20and%20HIV-1%20is%20the%20propensity%20for%20displaying%20host-derived%20glycans%20on%20entry%20spike%20proteins.%20Similarly%20displayed%20glycosylation%20motifs%20can%20serve%20as%20the%20basis%20for%20glyco-epitope%20mediated%20cross-reactivity%20by%20antibodies%2C%20which%20can%20have%20important%20implications%20on%20virus%20neutralization%2C%20antibody-dependent%20enhancement%20%28ADE%29%20of%20infection%2C%20and%20the%20interpretation%20of%20antibody%20titers%20in%20serological%20assays.%20From%20a%20panel%20of%20nine%20anti-HIV-1%20gp120%20reactive%20antibodies%2C%20we%20selected%20two%20%28PGT126%20and%20PGT128%29%20that%20displayed%20high%20levels%20of%20cross-reactivity%20with%20the%20SARS-CoV-2%20spike.%20We%20report%20that%20these%20antibodies%20are%20incapable%20of%20neutralizing%20pseudoviruses%20expressing%20SARS-CoV-2%20spike%20proteins%20and%20are%20unlikely%20to%20mediate%20ADE%20via%20Fc%5Cu03b3RII%20receptor%20engagement.%20Nevertheless%2C%20ELISA%20and%20other%20immunoreactivity%20experiments%20demonstrate%20these%20antibodies%20are%20capable%20of%20binding%20the%20SARS-CoV-2%20spike%20in%20a%20glycan-dependent%20manner.%20These%20results%20contribute%20to%20the%20growing%20literature%20surrounding%20SARS-CoV-2%20S%20cross-reactivity%2C%20as%20we%20demonstrate%20the%20ability%20for%20cross-reactive%20antibodies%20to%20interfere%20in%20immunoassays.%22%2C%22date%22%3A%222021-06-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-021-91746-7%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41598-021-91746-7%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-14T18%3A13%3A30Z%22%7D%7D%5D%7D
Mannar, D., Leopold, K., & Subramaniam, S. (2021). Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry. Scientific Reports, 11(1), 12448. https://doi.org/10.1038/s41598-021-91746-7 Cite
